RedHill Biopharma RDHL
NASDAQ RDHL
$0.65 +0.02 (+3.29%)
At close: Aug 20, 2026 · 10:57 AM UTC

RedHill Biopharma (RDHL) Receivables - Notes (2025)

RedHill Biopharma (RDHL) posted quarterly Receivables - Notes of $33000.0 for Q4 2025.

RedHill Biopharma (RDHL) Receivables - Notes (2025) Analysis & Trends

RedHill Biopharma (RDHL) has reported Receivables - Notes for 1 consecutive years, with $33000.0 the latest figure, recorded in Q4 2025.

  • In Q4 2025, Receivables - Notes changed N/A year-over-year to $33000.0; the TTM figure through Dec 2025 stood at $33000.0 (changed N/A YoY), while the FY2025 annual figure was $33000.0, changed N/A from the prior year.
  • Receivables - Notes held at $33000.0 in Q4 2025 per RDHL's latest filing.
  • Across five years, Receivables - Notes topped out at $33000.0 in Q4 2025 and bottomed at $33000.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 43.89 Bn 42.93 Bn -
2 Teva Pharmaceutical Industries 43.01 Bn 39.35 Bn 2.15 Bn
3 Zoetis 31.52 Bn 29.84 Bn 1.05 Bn
4 Takeda Pharmaceutical 28.61 Bn 22.81 Bn 5.10 Bn
5 United Therapeutics 22.17 Bn 19.51 Bn 683.80 Mn
6 Viatris 18.73 Bn 17.85 Bn 1.46 Bn
7 Neurocrine Biosciences 15.51 Bn 15.12 Bn 935.80 Mn
8 Elanco Animal Health 11.75 Bn 11.22 Bn 798.00 Mn
9 Dr Reddys Laboratories 10.12 Bn 9.96 Bn -
10 RedHill Biopharma 2.05 Bn 2.05 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2025 33,000.00